Related Experiment Video

Updated: Aug 18, 2026

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

Myelomonocytic leukaemia following cyclophosphamide therapy of rheumatoid disease

R R Love, J M Sowa

    Annals of the Rheumatic Diseases
    |December 1, 1975
    PubMed

    Abstract:

    A 69-year-old woman treated for 31 months with daily oral cyclophosphamide for refractory rheumatoid disease developed acute myelomonocytic leukemia 21/2 years after stopping the drug. The possibility of a casual association between the therapy and subsequent leukaemia is supported by the growing experience with cytotoxic agents.

    More Related Videos

    Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
    12:05

    Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

    Published on: November 3, 2018

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
    08:31

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

    Published on: October 17, 2025

    Related Experiment Videos

    Last Updated: Aug 18, 2026

    A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
    08:00

    A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

    Published on: October 14, 2016

    Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
    12:05

    Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

    Published on: November 3, 2018

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
    08:31

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

    Published on: October 17, 2025

    Related Concept Videos

    Disorders of Leukocytes01:27

    Disorders of Leukocytes

    Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
    Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

    Articles linked to this work by shared authors, journal, and citation graph.

    Public health oncology: a framework for progress in low- and middle-income countries.

    Annals of oncology : official journal of the European Society for Medical Oncology·2012

    Improving outcomes from breast cancer in a low-income country: lessons from bangladesh.

    International journal of breast cancer·2012

    Family history, BRCA mutations and breast cancer in Vietnamese women.

    Clinical genetics·2010

    The effects of tamoxifen on the vaginal epithelium in postmenopausal women.

    Journal of women's health & gender-based medicine·2000

    Symptoms associated with oophorectomy and tamoxifen treatment for breast cancer in premenopausal Vietnamese women.

    Breast cancer research and treatment·2000

    Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen.

    Cancer letters·1999

    Multiomics landscape of systemic sclerosis: from autoantibody-positivity to established disease.

    Annals of the rheumatic diseases·2026

    IgG4-related disease is not associated with an increased incidence of malignancy in a large, single-centre cohort.

    Annals of the rheumatic diseases·2026

    Early arthritis signs and symptoms revisited-is synovitis what we are assessing?

    Annals of the rheumatic diseases·2026

    Preclinical and clinical outcomes in patients with high rheumatoid factor levels treated with TNF inhibitors:a systematic review.

    Annals of the rheumatic diseases·2026

    Immune reset in rheumatic autoimmune disease: from a tantalising metaphor to a measurable therapeutic state.

    Annals of the rheumatic diseases·2026

    DNA methylation signatures distinguish gout from asymptomatic hyperuricaemia and converge with genetic risk at immune-metabolic loci.

    Annals of the rheumatic diseases·2026

    Catecholamine-Secreting Retroperitoneal Paraganglioma: A Case Report and Literature Review.

    Case reports in urology·2026

    Incidence and reasons for cancellation on the day of elective surgery: a systematic review and meta-analysis.

    Anaesthesia·2026

    CRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML.

    Genome medicine·2026

    Single-cell transcriptomics reveals transcriptional reprogramming and microenvironmental remodeling in ectopic ACTH/CRH-secreting pheochromocytomas.

    Journal of translational medicine·2026

    CUE domain-containing 2 promotes diffuse large B-cell lymphoma progression via PP2A-B55β degradation and shapes macrophage-mediated immune responses.

    Molecular biomedicine·2026

    FDXR upregulation by p63/p73 is a prognostic and therapeutic marker of adult T-cell leukemia/lymphoma.

    EMBO molecular medicine·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us